Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic failure of ACT in uncomplicated malaria in Goma
PACTR202605846123666Recruiting
- Sponsor
- MUMBERE HANGI STAN
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of dihydroartemisinin + piperaquine and artemether + lumefantrine in malaria (2 arms), sponsored by MUMBERE HANGI STAN. Primary endpoint: PCR-corrected adequate clinical and parasitological response at Day 28. Started Nov 2024; status: recruiting.
02
Drugs
dihydroartemisinin + piperaquineartemether + lumefantrine
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202605846123666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605846123666.